Heart failure pharmacotherapy aims to improve symptoms, reduce hospitalizations, and prolong survival in patients with reduced or preserved ejection fraction. Heart failure is a complex clinical syndrome resulting from structural or functional impairment of ventricular filling or ejection of blood. Contemporary management combines neurohormonal blockade, volume management, and emerging metabolic therapies.
What Is Heart Failure Pharmacotherapy?
Heart failure is broadly classified into heart failure with reduced ejection fraction (HFrEF, EF less than 40 percent), mildly reduced (HFmrEF, EF 40 to 49 percent), and preserved ejection fraction (HFpEF, EF 50 percent or greater). Pharmacological strategies differ by phenotype but share the goal of counteracting maladaptive neurohormonal activation involving the renin-angiotensin-aldosterone system and the sympathetic nervous system.
Drug Classes and Mechanisms
ACE inhibitors and ARBs reduce angiotensin II-mediated vasoconstriction, sodium retention, and cardiac remodeling. Beta-blockers including bisoprolol, carvedilol, and metoprolol succinate antagonize sympathetic overdrive, improving left ventricular function and reducing arrhythmic risk. Loop diuretics such as furosemide manage volume overload through inhibition of the Na-K-2Cl cotransporter in the loop of Henle. Digoxin inhibits the Na-K-ATPase pump, increasing intracellular calcium and enhancing myocardial contractility while also exerting vagotonic effects. Aldosterone antagonists spironolactone and eplerenone block mineralocorticoid receptors, reducing fibrosis and sodium retention. SGLT2 inhibitors empagliflozin and dapagliflozin improve outcomes in both HFrEF and HFpEF through mechanisms beyond glycemic control, including improved myocardial energetics and reduced inflammation. Angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan simultaneously inhibits neprilysin and blocks the AT1 receptor, enhancing natriuretic peptide activity while suppressing the RAAS.
Therapeutic Uses
Guideline-directed medical therapy for HFrEF typically includes a combination of an ACE inhibitor or ARNI, a beta-blocker, an aldosterone antagonist, and an SGLT2 inhibitor. Diuretics are used as needed for symptom relief of congestion. In HFpEF, SGLT2 inhibitors have demonstrated benefit, while diuretics are used for volume management. Digoxin is reserved for patients with atrial fibrillation or persistent symptoms despite optimized therapy.
Adverse Effects
ACE inhibitors and ARNI can cause hypotension, hyperkalemia, and angioedema. Beta-blockers may worsen acute decompensation if initiated too aggressively. Aldosterone antagonists carry a risk of hyperkalemia, particularly in patients with renal impairment. Digoxin has a narrow therapeutic index and can cause arrhythmias, visual disturbances, and gastrointestinal symptoms. SGLT2 inhibitors increase the risk of genitourinary infections and rarely cause euglycemic diabetic ketoacidosis.
Key Clinical Considerations
Therapy should be initiated at low doses and uptitrated to target doses used in landmark clinical trials rather than merely achieving symptom response. Renal function and electrolytes require close monitoring during initiation and titration of ACE inhibitors, ARNI, and aldosterone antagonists. Patient education on daily weight monitoring, dietary sodium restriction, and recognizing early signs of decompensation is critical.
Conclusion
The pharmacological management of heart failure has evolved substantially with the addition of SGLT2 inhibitors and ARNI to traditional neurohormonal blockade. A multi-drug approach tailored to ejection fraction and comorbidities reduces mortality, improves quality of life, and decreases hospitalization rates in this high-risk population.
